SEC Tracker › LENZ Therapeutics › Tables
Fiscal quarters (LENZ's year ends in late December) ← Scroll for earlier quarters
In thousands of dollars Q4 FY23 Dec 31, 2023 Q1 FY24 Mar 31, 2024 Q2 FY24 Jun 30, 2024 Q3 FY24 Sep 30, 2024 Q4 FY24 Dec 31, 2024 Q1 FY25 Mar 31, 2025 Q2 FY25 Jun 30, 2025 Q3 FY25 Sep 30, 2025 Q4 FY25 Dec 31, 2025 Q1 FY26 Mar 31, 2026 Q2 FY26 Jun 30, 2026 Q3 FY26 Sep 30, 2026 Revenue from contracts with customers — — — — year only 0 5,000 12,500 1,588* 1,901 5,486 3,384 Cost of goods and services sold — — — — year only 0 0 0 418* 1,076 280 454 Research and development 1* 10,537 6,945 6,451 5,868* 5,818 9,061 3,791 0* 0 0 0 Selling, general and administrative 5,453* 5,551 7,407 6,494 9,357* 11,113 12,796 27,596 39,633* 44,960 39,378 35,848 General and administrative 14,601* — — — — — — — — — — — Total operating expenses 25,555* 16,088 14,352 12,945 15,225* 16,931 21,857 31,387 — — — — Operating income (loss) (25,555)* (16,088) (14,352) (12,945) (15,225)* (16,931) (16,857) (18,887) (38,463)* (44,135) (34,172) (32,918) Interest income 851* 788 2,463 2,736 2,566* 2,323 2,246 2,201 2,986* 2,644 2,270 1,985 Other income (expense) 2,562* (1,348) 1,635 (6) 8* (11) 199 (14) (417)* 3 (13) (36) Income tax expense (benefit) year only — 0 0 1* — 500 0 2* — 3 0 Net income (loss) (22,918)* (16,648) (10,254) (10,215) (12,652)* (14,619) (14,912) (16,700) (35,896)* (41,488) (31,918) (30,969) Earnings per share, basic USD per share (0.39)* (3.53) (0.40) (0.38) — (0.53) (0.53) (0.59) (1.16)* (1.32) (1.02) (0.99) Earnings per share, diluted USD per share (0.39)* (3.53) (0.40) (0.38) — (0.53) (0.53) (0.59) (1.16)* (1.32) (1.02) (0.99) Weighted average shares, basic thousands of shares 58,166* 4,718 25,609 27,172 — 27,526 28,079 28,541 31,071* 31,353 31,374 31,420 Weighted average shares, diluted thousands of shares 58,166* 4,718 25,609 27,172 — 27,526 28,079 28,541 31,071* 31,353 31,374 31,420
Fiscal quarters (LENZ's year ends in late December) ← Scroll for earlier quarters
In thousands of dollars Q4 FY23 Dec 31, 2023 Q1 FY24 Mar 31, 2024 Q2 FY24 Jun 30, 2024 Q3 FY24 Sep 30, 2024 Q4 FY24 Dec 31, 2024 Q1 FY25 Mar 31, 2025 Q2 FY25 Jun 30, 2025 Q3 FY25 Sep 30, 2025 Q4 FY25 Dec 31, 2025 Q1 FY26 Mar 31, 2026 Q2 FY26 Jun 30, 2026 Q3 FY26 Sep 30, 2026 Cash and cash equivalents 184,259 200,357 84,035 41,046 20,158 23,042 37,608 25,399 25,179 24,772 24,208 30,553 Marketable securities 0 12,922 112,077 176,061 — — — — — — — — Marketable securities, non-current 0 — — — — — — — — — — — Accounts receivable — — — — 0 — — — 329 343 442 913 Inventory — — — — 0 — — 949 2,936 3,498 4,121 4,760 Prepaid and other current assets 2,160 3,281 3,124 3,483 2,773 3,769 3,969 3,876 5,800 6,141 8,716 3,921 Total current assets 188,021 216,674 199,350 220,704 211,917 197,859 213,602 206,997 301,412 268,367 233,282 206,897 Property and equipment, net 0 49 164 372 651 926 1,169 1,258 1,189 1,096 1,002 640 Right-of-use asset 321 578 1,727 1,533 1,338 1,069 959 847 734 619 521 421 Total assets 188,456 217,322 202,639 224,007 215,304 201,252 217,332 210,704 305,876 272,535 236,596 209,749 Accounts payable 250 7,131 4,406 2,762 4,257 3,661 2,854 4,323 4,167 10,929 6,648 5,517 Accrued liabilities 12,803 11,757 4,177 4,948 6,149 4,908 7,544 11,993 17,020 14,877 9,779 12,233 Total current liabilities 4,797 18,888 8,583 7,710 10,406 8,569 10,398 16,316 21,187 25,806 17,212 17,750 Lease liability, non-current 77 156 1,052 953 814 673 569 461 350 237 122 0 Total liabilities 4,874 19,155 9,718 8,727 11,220 9,242 10,967 16,777 21,537 26,043 17,334 17,750 Accumulated deficit (367,054) (111,893) (122,147) (132,362) (145,014) (159,633) (174,545) (191,245) (227,141) (268,629) (300,547) (331,516) Total stockholders' equity 183,582 198,167 192,921 215,280 204,084 192,010 206,365 193,927 284,339 246,492 219,262 191,999 Total liabilities and equity 188,456 217,322 202,639 224,007 215,304 201,252 217,332 210,704 305,876 272,535 236,596 209,749 Common shares outstanding (cover page) thousands of shares 58,237 25,534 27,497 27,501 27,543 28,146 28,522 31,290 31,354 31,354 31,420 31,421
Fiscal quarters (LENZ's year ends in late December) ← Scroll for earlier quarters
In thousands of dollars Q4 FY23 Dec 31, 2023 Q1 FY24 Mar 31, 2024 Q2 FY24 Jun 30, 2024 Q3 FY24 Sep 30, 2024 Q4 FY24 Dec 31, 2024 Q1 FY25 Mar 31, 2025 Q2 FY25 Jun 30, 2025 Q3 FY25 Sep 30, 2025 Q4 FY25 Dec 31, 2025 Q1 FY26 Mar 31, 2026 Q2 FY26 Jun 30, 2026 Q3 FY26 Sep 30, 2026 Net income (loss) (22,918)* (16,648) (10,254) (10,215) (12,652)* (14,619) (14,912) (16,700) (35,896)* (41,488) (31,918) (30,969) Stock-based compensation 2,305* 947 1,597* 2,191* 1,630* 2,555 2,845* 3,469* 3,678* 4,319 4,472* 4,134* Depreciation and amortization 4* 5 18* 10* 25* 36 19* 125* 107* 111 110* 109* Net cash from operating activities year only (23,937) (15,795)* (10,581)* (9,078)* (16,049) (11,508)* (8,588)* (33,025)* (33,582) (38,713)* (22,311)* Purchases of property and equipment 50* 0 133* 186* 149* 110 240* 439* 38* 18 16* 0* Net cash from investing activities 47,082* 18,000 (98,390)* (62,226)* (11,863)* 18,889 (414)* (4,333)* (89,810)* 33,161 37,754* 28,656* Proceeds from issuing common stock 0* 53,387 (3,563)* 29,774* (85)* 0 — — — — — — Net cash from financing activities 66* 171,268 (2,137)* 29,818* 53* 44 26,488* 598* 122,615* 14 395* 0* Net change in cash 1,271* 165,331 (116,322)* (42,989)* (20,888)* 2,884 14,566* (12,323)* (220)* (407) (564)* 6,345*
Compare with peers The peer list for this company is being put together from its industry's latest filings. Reload the page in a minute to see it.
Not investment advice. Not affiliated with the U.S. SEC.